. 2018 Feb 20;13(2):e0192627. doi: 10.1371/journal.pone.0192627

Table 3. Number of patients tested throughout mixed models and correlation with eGFR decline at different time-points.

Variable		n	correlation with GFR decline (adjusted p)
Variable		n	from BL toEoT	from BL toFU12	from BL to FU24
TDF	Y	111	0.0001	0.119	0.078
TDF	N	33	0.408	0.686	0.970
RBV	Y	115	0.0005	0.151	0.067
RBV	N	29	0.117	0.536	0.998
PI	Y	38	0.994	0.994	1.000
PI	N	106	<0.0001	0.024	0.016
INSTI	Y	110	<0.0001	0.031	0.046
INSTI	N	34	0.918	0.991	0.999
Age >45 years^*	Y	120	0.0001	0.032	0.1096
Age >45 years^*	N	24	0.4645	0.9969	0.9854
Hypertension	Y	34	0.9961	0.9126	0.9564
Hypertension	N	110	<0.0001	0.0595	0.0984
Metavir stage of fibrosis	F1	117	0.0028	0.0407	0.4627
	F2	17	0.6405	1.0000	0.9996
	F3	8	0.2521	0.9996	0.1427
Experienced to HCV treatment	Y	65	<0.0001	0.2631	0.0739
Experienced to HCV treatment	N	77	0.2198	0.343	0.8492
HCV since >12.9 years^*	Y	80	0.0035	0.094	0.1861
HCV since >12.9 years^*	N	39	0.3615	1.0000	0.9961
HIV since >16.9 years^*	Y	106	0.0002	0.0034	0.0319
HIV since >16.9 years^*	N	36	0,3547	1.0000	0.9998
Nadir CD4>100 cells/μL	Y	90	0.0035	0.2951	0.5598
Nadir CD4>100 cells/μL	N	43	0.0082	0.0813	0.2733
BL HCV-RNA< = 1,970,160^* IU/ml	Y	98	<0.0001	0.001	0.0879
BL HCV-RNA< = 1,970,160^* IU/ml	N	46	0.9723	1.0000	0.9739

GFR: glomerular filtration rate; n: number of patients; Y: yes; N: no; BL: baseline; EoT: end of treatment; FU12: 12 weeks after the end of treatment; FU24: 24 weeks after the end of treatment; TDF: tenofovir; RBV: ribavirin.

*Dichotomized as per ROC. Metavir stage of fibrosis is given according to stiffness evaluation by Fibroscan^®